HER2+ early breast cancer has been revolutionized by the development of HER2 directed therapy, which has significantly reduced breast cancer recurrence risk and improved overall survival. Dr. Hope S. Rugo reviews and discusses the available treatment options for this patient population, including:
- Individualized therapy to optimize the balance of efficacy and toxicity
- The addition of pertuzumab to a trastuzumab-based adjuvant regimen
- Improvement of pathologic complete response rates and invasive disease-free survival
- The addition of neratinib for patients with high-risk disease
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health Conferencing. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire activity as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Click here to obtain your CME credit: [ Ссылка ]
If you have questions regarding this enduring material activity, please contact us at certificates@amedcoemail.com.
